# HIV Risk Reduction in Subutex Injectors in Tbilisi

> **NCT01131273** · PHASE3 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 68 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** methadone
- **DRUG:** buprenorphine-naloxone (Suboxone) for 12 weeks

## Key facts

- **NCT ID:** NCT01131273
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2016-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01131273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01131273, "HIV Risk Reduction in Subutex Injectors in Tbilisi". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT01131273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*